Éñ¾µÝÖÊÊÇÖ¸Éñ¾Ä©ÉÒÊͷŵÄÌØÊ⻯ѧÎïÖÊ£¬ËüÄÜ×÷ÓÃÓÚÖ§ÅäµÄÉñ¾Ôª»òЧӦϸ°ûĤÉϵÄÊÜÌ壬´Ó¶øÍê³ÉÐÅϢת´ï¹¦Ð§¡£Éñ¾µÝÖʵÄÕý³£ÊͷŹØÓÚά³Ö»úÌåÕý³£µÄÐÄÀí¹¦Ð§Ê©Õ¹×ÅÖ÷Òª×÷Óã¬Í¬Ê±£¬Éñ¾µÝÖʵÄÊÍ·ÅÓëµ÷Àí·ºÆðÒ쳣ʱҲÓëһϵÁеIJ¡ÀíÀú³ÌÏà¹Ø£¬ÈçÒÖÓôÖ¢(Depression)¡¢³Éñ«(Addiction)¡¢ÅÁ½ðÉÊÏÖ¢(Parkinson's disease£¬PD)ºÍ°¢¶û×Ⱥ£Ä¬Ö¢(Alzheimer's disease£¬AD)µÈ ¡£ Òò´Ë£¬ÔÚ·Ö×Ó¡¢Ï¸°û¡¢»·Â·µÈ²ãÃæ׼ȷµØÆÊÎö¼ì²âÉñ¾µÝÖÊÊÇÔõÑù¼ÓÈë²¢µ÷ÀíÉÏÊöÐÄÀíºÍ²¡ÀíÀú³Ì£¬Äܹ»¸üÉîÈëµØÏàʶ¼²²¡µÄ·¢²¡»úÖÆ£¬²¢ÎªÁÙ´²Ò©ÎïµÄ¿ª·¢µÓÚ¨»ù´¡¡£
Éñ¾µÝÖʼ°Æä´úл²úÆ·ÆÕ±éÂþÑÜÓÚÖÐÊàºÍÍâÖÜÉñ¾ÏµÍ³£¬ÔÚά³Ö¸÷ÏîÉúÔËÆø¶¯ÖÐÆðןÜÊÇÖ÷ÒªµÄ×÷ÓÃÒѾ֤ʵ¡£Éñ¾µÝÖʵÄʧµ÷»òÔÓÂҺͶàÖÖÉñ¾¼²²¡Ç×½üÏà¹Ø£¬ÈçÅÁ½ðɼ²²¡(Parkinson's disease, PD)¡¢½¹ÂÇ¡¢
¾«ÉñÆÆËé¡¢ÒÖÓôºÍ°¢¶û×Ⱥ£Ä¬²¡(Alzheimer's disease, AD)µÈ¡£Òò´Ë£¬¸ßͨÁ¿¼ì²â¼°ÆÊÎöÉñ¾µÝÖÊÀàÎïÖÊ£¬¶ÔÕ¹ÏÖÉñ¾ÏµÍ³À༲²¡µÄ·¢²¡»úÖƺÍÕï¶ÏÖÎÁÆÓÐÖ÷ÒªµÄÑо¿ÒâÒå¡£
Éñ¾µÝÖÊÀàÎïÖʼì²âÁбí
×¢£º¹²¿É¼ì²â42ÖÖÖÐÐÄ̼´úлÎïÖÊ
¸ßͨÁ¿£º½ÓÄɸßËÙÊÕÂÞËÙÂÊÖÊÆ×ƽ̨£¬Í¬Î»ËØÄÚ±êÑéÖ¤£¬¿Éͬʱ¾ø¶Ô¶¨Á¿¶àÖÖÉñ¾µÝÖÊÀàÎïÖÊ
רҵЧÀÍ£ºÍêÉƵÄÊÛºóЧÀÍ£¬Ö§³Öµ½Êý¾Ý½ÒÏþ
? Ñù±¾ÒªÇó
Ö²Îï×éÖ¯£º200 mg/sample
¶¯Îï×éÖ¯Ñù±¾£º200 mg/sample
ѪÇ塢Ѫ½¬£º200 ¦ÌL/sample
ϸ°û£º1X107 cells/sample
·à±ã£º200 mg/sample
? Öü´æºÍÔËÊä
Òºµª»ò-80¡ãCÉúÑÄ£»×ãÁ¿¸É±ùÔËÊ䣬×èÖ¹Öظ´¶³ÈÚ
? ¼ì²âƽ̨
Qtrap 6500+, Sciex
? ͨÀýÖÜÆÚ
ʵÑé¼ì²â£º30¸ö×ÔÈ»ÈÕ£¨´ÓÊÕµ½¿Í»§Ô¤¸¶¿î²¢ÊÕµ½ÑùÆ·Ö®ÈÕÆð£©
Êý¾ÝÆÊÎö£º5¸ö×ÔÈ»ÈÕ
- ×é֯ϸ°ûµÈÑù±¾ÖÐÉñ¾µÝÖÊÀàÎïÖÊÅжÏ
- Éñ¾ÏµÍ³À༲²¡µÄ·¢²¡»úÖƺÍÔçÆÚÕï¶Ï
- ËÇÁÏÌí¼Ó¼Á
- ÎÛȾÎïÉñ¾¶¾ÐÔµÄÉúÎï±ê¼ÇÎï
? »ùÓÚ¶àÖÖѪ½¬Éñ¾µÝÖÊת±äµÄÒÖÓôÖ¢Õï¶Ï£ºÒ»Ïî°ÐÏò´úл×éѧÑо¿
Ñо¿¹¤¾ß£º ÒÖÓôÖ¢»¼Õß
ÆÚ¿¯£º Translational Psychiatry
Ó°ÏìÒò×Ó£º 6.22
ʱ¼ä£º 2018Äê
ÖضÈÒÖÓôÖ¢(Major Depressive Disorder, MDD)ÊÇÒ»ÖÖʹÈËÐéÈõµÄ¾«Éñ¼²²¡¡£ÖÐÊàºÍÍâÖÜÉñ¾µÝÖʵÄÔÓÂÒÊÇMDDµÄÒ»¸öÌØÕ÷£¬MDD»¼ÕßµÄÐí¶àÉñ¾µÝÖÊÀàÎïÖʶ¼Êܵ½×ÌÈÅ¡£ÏÖÔÚ£¬MDDµÄÕï¶ÏÖ÷ÒªÒÀÀµ¾«Éñ¿ÆÒ½Éú¶Ô֢״ȺµÄÖ÷¹Ûʶ±ð£¬ÎóÕïÂʽϸߣ¬ÆäÖÐÓÉÓÚÁÙ´²Ö¢×´ÏàËÆ£¬Ë«ÏàÇéÐ÷ÕÏ°(Bipolar Disorder, BD)²¡Àý¾Í³£±»ÎóÕïΪMDD¡£²»µ½Ò»°ëµÄMDD»¼Õߣ¨ÔÚÐí¶à¹ú¼Ò£¬²»µ½10%£©½ÓÊÜÁËÓÐÓõÄÖÎÁÆ¡£Òò´Ë£¬MDDµÄ¿Í¹ÛÕï¶ÏÒªÁ콫¾ßÓÐÏ൱´óµÄÁÙ´²¼ÛÖµ¡£È»¶ø£¬ÏÖÔÚ»¹Ã»ÓÐÕë¶ÔÕâÖÖ¼²²¡µÄ¿Í¹ÛʵÑéÊÒÕï¶Ï²âÊÔ¡£
? Ñо¿Ð§¹û
ʹÓÃÆøÏàÉ«Æ×-ÖÊÆ×ÁªÓÃ(Gas Chromatography-Mass Spectrometry, GC-MS)ºÍÒºÏàÉ«Æ×-´®ÁªÖÊÆ×(LC-MS/MS)¶Ô19ÖÖÉñ¾µÝÖʺÍÏà¹Ø´úлÎï¾ÙÐж¨Á¿ÆÊÎö£¬·¢Ã÷GABAͨ·ºÍ¶ù²è·Ó°·Í¨Â·±È5-ôÇÉ«°·Í¨Â·¶ÔMDDµÄÕï¶ÏЧ¹û¸üºÃ¡£ÇÒ·¢Ã÷ÁËËÄÖÖѪ½¬´úлÎDOPN¡¢GABA¡¢TyraºÍKyn£©¿ÉÒÔÓÐÓÃÇø·ÖMDD»¼ÕߺͿµ½¡±ÈÕÕÕߣ¬²¢ÇÒ¿ÉÒÔÓÐÓÃÇø·ÖMDDÊÜÊÔÕßÓëË«ÏàÇéÐ÷ÕÏ°(Bipolar Disorder, BD)ÊÜÊÔÕß¡£ÕâЩЧ¹ûÅúעʹÓÃGC-MSÍŽáLC-MS/MS°ÐÏò´úл×éѧҪÁ죬ȷ¶¨µÄDZÔÚµÄѪ½¬Õï¶Ï´úлÎï×éÄܹ»¸ß¾«¶ÈµØ½«ÒÖÓôÖ¢»¼ÕßÓ뿵½¡±ÈÕÕ×éºÍBDÊÜÊÔÕßÇøÍÑÀëÀ´¡£ÕâЩ·¢Ã÷ÓÐÖúÓÚÕ¹ÏÖMDDµÄ·Ö×Ó·¢²¡»úÖÆ£¬Îª¼²²¡µÄÕï¶ÏºÍÔ¤ºó¼ì²âµÓÚ¨»ù´¡¡£
? Ñо¿Ë¼Ð÷
? Ч¹ûչʾ
ÆÀ¹ÀÊ״α¬·¢Ê±·þÓÿ¹ÒÖÓôÒ©ÎïµÄ³õÖÎMDD»¼ÕßÓ뿵½¡±ÈÕÕ¸öÌåµÄѪ½¬Ñù±¾£¬»ñµÃÁ½×éÖвî±ðÏÔÖøµÄ´úлÎͼ1£©¡£Ê¹ÓÃÏà¹ØÐÔÆÊÎö£¨Í¼2A£©¶Ô²î±ð´úлÎï¾ÙÐй¦Ð§·Ö×é²¢¾ÙÐÐROCÆÊÎö£¨Í¼2B-D£©£¬·¢Ã÷GABAͨ·ºÍ¶ù²è·Ó°·Í¨Â·±È5-ôÇÉ«°·Í¨Â·¶ÔMDDµÄÕï¶ÏЧ¹û¸üºÃ¡£Ê¹ÓöþÔªÂß¼»Ø¹éÆÊÎö²¢¾ÙÐÐROCÆÊÎö·¢Ã÷ÓÉDOPN¡¢GABA¡¢TyraºÍKyn´úлÎï×é³ÉµÄÉúÎï±ê¼ÇÎï×é¿ÉÒÔÌṩMDD»¼ÕߺͿµ½¡±ÈÕÕ×éÖ®¼ä×îÏÔÖøµÄÎó²î(ͼ3A)¡£Ê¹ÓÃÒÑÅжϵĴúлÎï¹¹½¨PLS-DA£¬»ñµÃÓëROCÆÊÎöÒ»ÖµÄЧ¹û£¨Í¼3B£©¡£¶ÔËÄÖÖѪ½¬´úлÎDOPN¡¢GABA¡¢TyraºÍKyn£©µÄŨ¶È¾ÙÐÐÁË×ÔÁ¦Á¿»¯ÇÒ¾ÙÐÐROCÆÊÎö£¨Í¼3C¡¢D£©£¬Ð§¹ûÅú×¢ÕâЩѪ½¬´úлÎï¿ÉÒÔÓÐÓÃÇø·ÖMDDÊÜÊÔÕߺͿµ½¡±ÈÕÕÕßÇÒ¿ÉÒÔÓÐÓÃÇø·ÖMDDÊÜÊÔÕßÓëBDÊÜÊÔÕß¡£
? ÎÄÏ×·ÖÏí
Pan Jun-Xi, Xia Jin-Jun, Deng Feng-Li et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study [J]. Transl Psychiatry, 2018, 8: 130.